Trial Profile

A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jan 2025 Results assessing the safety and feasibility of single UM171-expanded single CB unit transplantation in frontline tandem auto/allo HCT for HR/ultra-HR MM patients published in the Transplantation and Cellular Therapy
10 Dec 2024 Results examining the outcome of patients with poor outcome TP53 or EVI1 anomalies who were transplanted with a single UM171 CBT during the course of phase I-II(n=1) and phase II(n=9) trial, presented at the 66th American Society of Hematology Annual Meeting and Exposition
06 Feb 2024 Planned End Date changed from 23 Sep 2025 to 17 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com